Jackson Hatfield
Family Medicine · Thomasville, GANPI 1316238744
Payments from drug & device makers
Across 454 payments — averaging $16.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$997
- Pfizer$736
- Boehringer Ingelheim$658
- Bayer$558
- Lilly USA, LLC$547
- plus $3K from 33 others
What the payments were for
- Food & beverage$7,574100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 63 | $1,095 |
| AbbVie(2 entities) | 63 | $997 |
| Pfizer | 52 | $736 |
| Boehringer Ingelheim | 33 | $658 |
| Bayer | 29 | $558 |
| Lilly USA, LLC | 36 | $547 |
| AstraZeneca | 26 | $545 |
| GSK | 38 | $472 |
| Teva Pharmaceuticals USA, Inc. | 15 | $278 |
| Amgen | 14 | $232 |
| Johnson & Johnson | 8 | $172 |
| Merck | 11 | $163 |
| Exact Sciences | 8 | $134 |
| Novartis | 5 | $93 |
| Astellas Pharma US Inc | 4 | $77 |
| Biohaven Pharmaceuticals, Inc. | 5 | $73 |
| Ironwood Pharmaceuticals, Inc | 4 | $73 |
| Veran Medical Technologies, Inc. | 1 | $70 |
| Axsome Therapeutics, Inc. | 2 | $52 |
| Amarin Pharma, Inc. | 3 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $44 |
| Insulet Corporation | 3 | $44 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $42 |
| Corcept Therapeutics | 2 | $41 |
| Dexcom, Inc. | 2 | $36 |
| Esperion Therapeutics, Inc. | 2 | $36 |
| Avanir Pharmaceuticals, Inc. | 2 | $24 |
| Phathom Pharmaceuticals, Inc. | 5 | $22 |
| Vertex | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| CGG Medical Inc | 1 | $18 |
| Almatica Pharma LLC | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Coloplast | 1 | $16 |
| Shield Therapeutics Inc | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$114
How this compares
$7,574 in reported general payments places this provider in the 90th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 225 | $177,787 |
| EliquisApixaban | 137 | $125,699 |
| OzempicSemaglutide | 94 | $102,889 |
| TrulicityDulaglutide | 67 | $86,845 |
| KerendiaFinerenone | 60 | $66,984 |
| MounjaroTirzepatide | 62 | $66,631 |
| FarxigaDapagliflozin Propanediol | 55 | $64,106 |
| RybelsusSemaglutide | 27 | $46,912 |
| XareltoRivaroxaban | 40 | $38,898 |
| EntrestoSacubitril/Valsartan | 60 | $38,813 |
| JanuviaSitagliptin Phosphate | 42 | $31,654 |
| Tresiba Flextouch U-100Insulin Degludec | 64 | $29,967 |
| LinzessLinaclotide | 39 | $29,058 |
| RexultiBrexpiprazole | 14 | $20,116 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $18,202 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $658 | $184,529239 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $547 | $153,475129 claims |
| Novo NordiskOzempic, Rybelsus | $1,095 | $149,801121 claims |
| PfizerEliquis, Abrysvo | $736 | $132,140158 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $545 | $74,53666 claims |
| BayerKerendia | $558 | $66,98460 claims |
| Johnson & JohnsonXarelto | $172 | $38,89840 claims |
| NovartisEntresto | $93 | $38,81360 claims |
| MerckJanuvia | $163 | $31,65442 claims |
| AbbVieLinzess | $997 | $29,05839 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $472 | $26,06946 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $43 | $20,11614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Thomasville
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.